EcoDrugPlus

Neurotrophic Receptor Tyrosine Kinase 2

Ensembl ID : ENSLACG00000002710
Gene Symbol: NTRK2
4 Cross references
286 Possible Orthologues:

Nicastrin

Ensembl ID : ENSLACG00000009662
Gene Symbol: NCSTN
3 Cross references
203 Possible Orthologues:

Nicotinamide Phosphoribosyltransferase

Ensembl ID : ENSLACG00000004482
Gene Symbol: NAMPT
4 Cross references
235 Possible Orthologues:

Nischarin

Ensembl ID : ENSLACG00000018599
Gene Symbol: NISCH
2 Cross references
209 Possible Orthologues:

Nitric Oxide Synthase 2

Ensembl ID : ENSLACG00000017704
Gene Symbol: NOS2
3 Cross references
165 Possible Orthologues:

Notch Receptor 1

Ensembl ID : ENSLACG00000017995
Gene Symbol: NOTCH1
3 Cross references
267 Possible Orthologues:

Nuclear Factor Kappa B Subunit 1

Ensembl ID : ENSLACG00000002751
Gene Symbol: NFKB1
4 Cross references
200 Possible Orthologues:

Nuclear Factor Kappa B Subunit 2

Ensembl ID : ENSLACG00000016308
Gene Symbol: NFKB2
4 Cross references
124 Possible Orthologues:

Nuclear Receptor Subfamily 1 Group H Member 2

Ensembl ID : ENSLACG00000015170
Gene Symbol: NR1H2
4 Cross references
304 Possible Orthologues:

Nuclear Receptor Subfamily 1 Group H Member 3

Ensembl ID : ENSLACG00000018964
Gene Symbol: NR1H3
2 Cross references
391 Possible Orthologues:

Nuclear Receptor Subfamily 1 Group H Member 4

Ensembl ID : ENSLACG00000017655
Gene Symbol: NR1H4
4 Cross references
387 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 1

Ensembl ID : ENSLACG00000015535
Gene Symbol: NR3C1
4 Cross references
278 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).